MD&A · 2025
In this section4 topics
Overview of Operations
Overview of Operations
Operating Results Overview for the year 2025
For the fiscal year 2025, the Group reported total revenues of 386.73 million Baht, an increase of 40.86 million Baht or 11.81% compared to the previous year. The primary driver was the success of the market expansion strategy for laboratory products, which resulted in sales revenue reaching 111.87 million Baht, a growth of 37.96%. Meanwhile, revenue from services continued to expand by 4.34%, despite intense market competition and policy changes by the National Health Security Office (NHSO) regarding fully-funded fetal chromosome screening services. The Group proactively adjusted its strategy by offering products aligned with the aforementioned policy to ensure eligibility for reimbursement at rates specified by the NHSO. This approach enabled the Group to effectively maintain its existing customer base and expand its services to new recipient groups.
In terms of cost management efficiency, the Group recorded a gross profit of 162.84 million Baht, representing a margin of 42.11% of total revenue. This reflects a robust performance, remaining close to the previous year's margin of 42.89%,despite pricing strategy adjustments made in response to government policies and heightened market competition. Net profit for the year amounted to 45.33 million Baht, a slight decrease of 9.63% from the previous year. This was primarily driven by a strategic decision to increase selling and administrative expenses to strengthen the corporate foundation and enhance the capacity for sustainable long-term revenue growth.
However, when considering the operating results for the fourth quarter of 2025 compared to the previous quarter (QoQ), the Group demonstrated significant and clear improvement. Total revenue reached 144.23 million Baht, an increase of 60.02%. The most prominent growth signal came from sales revenue, which surged by 280.58% from the previous quarter. These factors led to a net profit for the fourth quarter of 26.00 million Baht, representing an exceptional growth of 275.72% compared to the third quarter. This reflects the Company’s agility and swift market responsiveness, which will serve as significant momentum for the performance in the following year.
Operating Results & Financial Condition
Operating Results & Profitability
Revenue Structure
The Group reported total revenue of 386.73 million Baht, an increase of 40.86 million Baht or 11.81% compared to the previous year. This growth was driven by the following key factors:
Revenue from laboratory equipment and reagents sales: This segment reached 111.87 million Baht, growing by 37.96% year-on-year. This success reflects our strategic focus on laboratory products. We have successfully expanded our market through various models, including direct equipment sales, equipment placement paired with monthly reagent supply, and the distribution of specialized reagents. these efforts have effectively stabilized our income and expanded our customer base.
Revenue from services : Totaling 267.64 million Baht, this segment grew by 4.34%. Despite intense competition and changes in the National Health Security Office (NHSO) policy—which now fully funds fetal chromosome screening and caused a slight 0.07% slowdown in reproductive health revenue—the Group adapted quickly. We introduced products that align with NHSO reimbursement rates to maintain our market share. Notably, our specialized services showed strong growth:Technology-driven services increased by 65.38% due to our technical expertise, Other screening services rose by 24.48%, driven by cancer screening (launched in Q3/2024) and the introduction of Advanced Therapy Medicinal Product (ATMP) services in 2025.
Other income: Decreased by 1.06 million Baht or 12.80%, mainly due to lower market interest rates for deposits.
The Group’s revenue for the three-month period ended December 31, 2025, showed clear growth, increasing by 54.10 million Baht or 60.02% compared to the previous quarter (QoQ).This reflects a strong recovery in business activities and a continuous rise in demand. The growth was significantly supported by sales revenue, which surged by 280.58% due to our aggressive product distribution strategy. At the same time, the core service business continued to expand by 5.90%. Despite the impact of NHSO policy changes, our ability to adjust strategies and offer market-relevant products helped us reach new customers effectively. This performance demonstrates the Group’s flexibility and the strong confidence customers have in our service quality.
Gross Profit and Gross Profit Margin from Sales
For the year ended December 31, 2025, the Group’s gross profit from sales reached 48.92 million Baht, representing a gross profit margin of 43.73%.This marks a significant increase of 24.37 million Baht or 99.27% compared to the same period last year. This growth was driven by the successful expansion into the laboratory product segment, including direct equipment sales, equipment placements bundled with monthly reagent supplies, and the distribution of specialized reagents to both public and private sector clients. These initiatives led to a 37.96% increase in sales revenue. Furthermore, improved cost management allowed the Group to raise its gross profit margin from 30.28% in the previous year to 43.73% in the current year.
For the three-month period ended December 31, 2025, the Group reported a gross profit from sales of 30.06 million Baht, or a gross profit margin of 45.11%.This represents an impressive leap of 324.58% compared to the previous quarter (QoQ). The primary driver was the exceptional growth in product sales, which surged by 280.58%. Additionally, the gross profit margin improved slightly from 40.43% in the previous quarter to 45.11%. This improvement reflects the Group’s ability to maintain strong profitability while achieving substantial sales growth.
Gross Profit and Gross Profit Margin from Services
For the year ended December 31, 2025, the Group’s gross profit from services was 106.70 million Baht, representing a gross profit margin of 39.87%. This is a decrease from 115.52 million Baht, or a 45.04% margin, in the previous year. This change was primarily due to intensified competition in our core service business and a strategic shift in our product mix to align with the National Health Security Office (NHSO) policy, which now provides fully-funded fetal chromosome screening. Although this strategic move led to a lower profit margin per unit, it effectively allowed the Group to retain its existing customer base and reach new service users. Furthermore, the Group maintained overall profitability stability by expanding into high-growth areas, particularly technology-driven services and cancer screening, which helped offset the margin slowdown in core services. Despite rising service costs—partly due to overseas sample analysis for specialized services—our commitment to improving laboratory efficiency and resource management has preserved our technical advantage. This ensures continued customer confidence despite external challenges and shifts in government policy.
On a quarter-over-quarter basis, the Group reported a gross profit from services of 29.35 million Baht, an increase of 10.17% compared to the previous quarter (QoQ).This growth aligns with the 5.90% increase in service revenue during this period. The gross profit margin also improved from 37.31% in the previous quarter to 38.81%. Despite a higher proportion of revenue coming from products aligned with NHSO policy, the Group demonstrated strong resilience in maintaining profit levels and a consistent ability to generate robust total revenue.
Operating Expenses
For the year ended December 31, 2025, the Group’s operating expenses totaled 114.67 million Baht, representing 29.66% of operating revenue. This is an increase of 17.42 million Baht, or 17.91%, compared to the previous year.An analysis of these expenses is as follows:
Selling Expenses: Increased by 9.67 million Baht, or 24.54%. This was primarily due to the expansion of the sales team to support revenue growth in both laboratory products and new services. Additionally, marketing and promotional activities were intensified as part of our strategy to expand our customer base and promote both existing and newly launched services.
Administrative Expenses: Increased by 7.67 million Baht, or 13.58%. The main factors included the recognition of director bonuses paid during the year and increased international travel expenses for business networking and sourcing new technologies. Furthermore, depreciation costs rose following investments in IT infrastructure, including high-performance storage systems and servers, to enhance operational stability and support increasing transaction volumes.
On a quarter-over-quarter basis, total operating expenses were 33.09 million Baht, an increase of 19.50%.This was mainly driven by a 24.58% rise in selling expenses due to aggressive promotional activities, public relations, and participation in exhibitions to build brand awareness for our products and services. Notably, the overall increase in expenses remained significantly lower than the total revenue growth of 60.02% in the same quarter. This demonstrates the Group’s efficiency in cost management and operational planning.
Liquidity & Capital Adequacy
Key Financial Ratios
The Return on Equity (ROE) for the year ended December 31, 2025, stood at 8.33%, a decrease from 12.98% in the same period of the previous year.The primary reason for this decline was the decrease in net profit, resulting from competitive pressures in the core service business and higher operating expenses. Despite this, the Company successfully expanded its customer base for new products, which offset the slowdown in core services. Additionally, the average shareholders’ equity for this period was higher than in the previous year. This expansion of the equity base also contributed to the decrease in ROE from an accounting perspective.
The Current Ratio as of December 31, 2025, stood at 4.58, a decrease from 11.27 in the same period of the previous year. Similarly, the Quick Ratio decreased to 3.42 from 6.39. Although both ratios declined, they remain at a very high level. This change was primarily a result of an increase in current liabilities, such as trade payables and payables for assets, which is consistent with the Company's business expansion and project investments.
The Average Collection Period for the year ended December 31, 2025, was 109.81 days an increase from 56.22 days in the same period of the previous year. This increase is primarily a result of our strategic market expansion into the public sector, particularly through the reagent-rental model. Public sector clients typicallyhave longer payment terms than their private sector counterparts, which directly resulted in the extended average collection period. However, the level of receivables remains consistent with the strong sales growth observed in the fourth quarter.
The Average Inventory Period for the year ended December 31, 2025, was 55.28 days, an increase from 38.56 days in the same period of the previous year. This was a result of proactive inventory management, where the Company increased its stock of products and raw materials in advance. This strategic move ensures that we can respond to customer demand promptly and maintain a reliable supply of products.
The Average Payment Period for the year ended December 31, 2025, stood at 86.53 days, a significant increase from 32.75 days in the same period of the previous year. This reflects an enhanced ability to manage cash flow and optimize trade terms with suppliers.
The Debt-to-Equity Ratio as of December 31, 2025, was 0.27, an increase from 0.13 in the same period of the previous year. This was a result of increased trade payables to support business expansion. However, the ratio remains at a very low level, reflecting a strong financial structure and low financial risk.
Asset Management Capability
Assets
As of December 31, 2025, the Group reported total assets of 701.85 million Baht, an increase of 94.26 million Baht or 15.51% from the end of 2024. This growth was primarily driven by increases in trade receivables and prepaid expenses to prepare for new products launching next year, along with inventory management aligned with sales expansion. Additionally, the Group continued to invest in non-current assets to drive long-term growth. Key investments include: Developing an Automated Biobank system in collaboration with the public sector to support Advanced Therapy Medicinal Products (ATMP), Developing CAR-T Cell products for blood cancer treatment. And investing in technology transfer agreements for the production of prototype immunotherapy cells, specifically Dendritic cells (DCs) and Cytokine-induced killer cells (CIK). These strategic investments are designed to generate significant future benefits for the Group.
Debt Securities with Financial Ratio Requirements
Debt Securities with Financial Ratio Requirements Issued?
No
Factors That May Affect Financial Condition
Factors or Incidents That May Materially Affect Financial Condition
The laboratory industry in 2025 continues to face intense competition driven by rapid technological advancements, increasingly stringent regulatory requirements, and the growing demand for laboratory testing services. Domestic operators also face challenges related to limitations in investment capital, technological capabilities, and marketing strategies when compared with multinational and foreign companies that possess stronger financial resources and technological advantages.
In addition, medical equipment manufactured domestically has not yet been widely accepted among medical professionals. As a result, the industry continues to rely on imported advanced technologies for service delivery and production processes, which may lead to higher costs of products and services in line with the increasing complexity of such technologies. Key factors affecting competitive conditions in the industry include:
1. Advancements in Medical Technology and Digital Transformation
Advancements in laboratory technologies, such as Next Generation Sequencing (NGS), automation systems, and bioinformatics data analysis, require operators to continuously invest in modern equipment and technologies to enhance accuracy, efficiency, and turnaround time. In addition, the adoption of advanced technologies such as Artificial Intelligence (AI), advanced analytics, and Laboratory Information Management Systems (LIMS), as well as emerging digital health trends including Telemedicine and At-home Diagnostic Kits, play an important role in improving service quality and operational efficiency, thereby strengthening the competitiveness of industry operators.
2. Regulatory Requirements and Laboratory Standards
The medical laboratory industry is subject to regulatory oversight and must comply with relevant standards and requirements, particularly international standards such as ISO 15189 for medical laboratories and ISO 17025 for testing and calibration laboratories. These standards serve as key indicators of the quality, accuracy, and reliability of laboratory results. Laboratories that consistently maintain high standards of quality and effective quality control systems are better positioned to build trust and confidence among physicians and service users, which represents an important competitive advantage.
3. Technology Costs and Competition in Pricing and Service Quality
Advanced medical equipment and technologies are largely imported, resulting in operational costs that may fluctuate in line with technology prices, exchange rates, and equipment complexity. At the same time, the laboratory industry faces competition in terms of pricing, quality of test results, turnaround time, and service standards. Operators therefore need to manage costs efficiently while continuously improving service quality and differentiating their services to maintain competitiveness and strengthen trust among physicians and service users.
4. Mergers, Acquisitions, and Strategic Partnerships
Trends in mergers, acquisitions, and strategic collaborations among laboratories, hospitals, research institutions, and healthcare partners have continued to increase as operators seek to expand service capabilities, develop new diagnostic services, and create additional business opportunities. Larger operators generally benefit from economies of scale, modern infrastructure, and broader service networks, which support business growth and enhance their competitive position within the industry.
5. Development of Specialized Professionals
Laboratory services require personnel with specialized knowledge, expertise, and professional experience. Operators therefore place significant emphasis on the continuous development of employee skills and professional competencies to keep pace with technological advancements and evolving industry requirements. Such efforts are essential to maintaining service quality and sustaining long-term competitiveness.
